Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2555841 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL2550785 | 0.89 | ADORA2A (0.79) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL2550783 | 0.89 | ADORA2A (0.79) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL2556664 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL27887643 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL2555110 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL27887645 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL2555106 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL27904499 | 0.86 | ADORA2A (0.76) | ADORA2AADORA1ADORA3ADORA2BPDE10A | |
| SCHEMBL2548740 | 0.82 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2BPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | claimed |
| CN-102892761-A | 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists | PALOBIOFARMA SL | 2013-01-23 | — | — | CN | claimed |
| EP-2552909-B1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2015-03-11 | — | — | EP | disclosed |
| US-8796284-B2 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2014-08-05 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
| EP-2552909-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | Palobiofarma, S.L. (ES) | 2013-02-06 | — | — | EP | disclosed |
| CN-102892761-A | 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists | PALOBIOFARMA SL | 2013-01-23 | — | — | CN | disclosed |
| WO-2011121418-A1 | 4 - AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.